Tag: KGAA
Biocorp and Merck KGaA sign new partnership for smart drug delivery – 10/10/2022 at 07:54
(AOF) – French healthcare company Biocorp and pharmaceutical group Merck KGaA, based in Darmstadt, Germany, are joining forces for the development and global distribution of a specific version of Mallya…
Biocorp: Collaboration agreement with Merck KGaA
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Biocorp: collaboration agreement with Merck KGaA
(CercleFinance.com) – Biocorp indicates that it has entered into an agreement with Merck KGaA for the development and supply of a specific version of its Mallya device as an accessory…
Merck KGaA: Collaboration agreement with Biocorp
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Merck KGaA: license agreement with Chinese Biocytogen
(CercleFinance.com) – Merck KGaA announced on Thursday the signing of a license agreement with the Chinese biotechnology company Biocytogen Pharmaceuticals, whose platform it will use to discover new antibodies. Under…
Merck KGaA: Licensing agreement with Chinese Biocytogen
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Merck KGaA: Collaboration agreement with Micron
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Merck KGaA: collaboration agreement with Micron
(CercleFinance.com) – German chemicals and pharmaceuticals group Merck announced on Wednesday that it has partnered with US memory maker Micron Technology to develop more sustainable gas supply technologies for the…
Merck KGaA: EU authorizes new anti-lung cancer drug
(CercleFinance.com) – Merck KGaA announced this weekend that the European Commission has approved the marketing of its Tepmetko tablet for the treatment of non-small cell lung cancer (NSCLC). The Brussels…
Merck KGaA: favorable follow-up data for Bavencio
(CercleFinance.com) – Merck KGaA presented on Friday follow-up data confirming the long-term positive phase III results obtained by its immunotherapy Bavencio in the treatment of advanced urothelial carcinoma. These results,…
Merck KGaA: Favorable follow-up data for Bavencio
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Merck KGaA: License Option Agreement with Quris
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…